Multiple Myeloma DFCI 10-106

Phase III study of the initial management of myeloma in patients up to 65 years of age.

Objective

To enroll eligible participants:

> 10% monocolonal plasma cells in bone marrow, monocolonal protein in serum and/or urine and myeloma related organ dysfunction (1 or more of CRAB). Pts must by symptomatic with measurable disease

Ages 18-65; ECOG 0-2;

Negative HIV test

Trial details: A randomized, phase III study comparing conventional dose treatment using a combination of lenalidomide, bortezomib and dexamethasone (RVD) to high dose treatment with peripheral stem cell transplant in the initial management of myeloma in patients up to 65 years of age.

Clinical Trial Categories

  • Multiple Myeloma
Contact
Rebecca Buscanera, RNC, BSN at 508-862-5799
or rbuscanera@capecodhealth.org
How to Participate

Speak to your oncologist at the Cape Cod Healthcare Regional Cancer Network or contact one of our experienced research nurses:

 

Rebecca Buscanera, RN - 508-862-5799

Christine Davenport, RN - 508-862-5745

 

Available at the Davenport-Mugar Cancer Center - Cape Cod Hospital

 

Location

  • Regional Cancer Network